b
r
c
easi
earli
detect
infect
inflamm
essenti
earli
effect
treatment
studi
pegyl
micel
design
micel
levofloxacin
radiolabel
tco
develop
potenti
radiotrac
detect
infectioninflamm
radiolabel
effici
vitro
stabil
bacteri
bind
tclevofloxacin
tcmicel
compar
aim
studi
formul
compar
tclevofloxacin
tcmicel
infect
inflamm
agent
differ
mechan
accumul
infect
inflamm
site
pegyl
micel
design
particl
size
nm
proper
character
properti
high
radiolabel
effici
achiev
tclevofloxacin
tcmicel
radiolabel
effici
remain
stabl
insignific
alter
radiotrac
h
although
vitro
bacteri
bind
tclevofloxacin
higher
tcmicel
tcmicel
may
also
evalu
potenti
agent
due
long
circul
passiv
accumul
mechan
infectioninflamm
site
radiopharmaceut
agent
exhibit
potenti
result
design
character
radiolabel
effici
vitro
bacteri
bind
point
view
diagnosi
infect
help
radiolog
imag
modal
comput
tomographi
ct
ultrasonographi
us
magnet
reson
imag
mri
provid
noninvas
diagnosi
accur
indic
area
lesion
depend
basi
anatom
imag
techniqu
infect
detect
format
morpholog
alter
therefor
earli
stage
detect
possibl
use
routin
medic
imag
modal
especi
deepli
seat
infect
exampl
osteomyel
intraabdomin
infect
endocard
purpos
use
scintigraph
imag
modal
gamma
scintigraphi
singl
photon
emiss
comput
tomographi
spect
positron
emiss
tomographi
pet
hybrid
imag
modal
compris
spectct
petct
petmri
provid
physiolog
metabol
inform
lesion
specif
radiopharmaceut
search
obtain
lesion
imag
physiolog
metabol
inform
earli
stage
microbi
infect
tclabel
leukocyt
first
radiopharmaceut
abil
imag
deepli
seat
infect
indic
region
inflamm
howev
cumbrou
method
one
commonli
face
disadvantag
detect
infect
nonspecif
tracer
perform
includ
gacitr
radiolabel
nonspecif
immunoglobulin
human
polyclon
immunoglobulin
hig
liposom
avidinbiotin
system
apart
nonspecif
tracer
specif
tracer
also
develop
radiolabel
white
blood
cell
includ
inoxinelabel
leukocyt
tchmpaolabel
leukocyt
antigranulocyt
antibodi
antibodi
fragment
chemotact
peptid
cytokin
platelet
ffdg
antibiot
antimicrobi
peptid
although
mani
altern
exist
develop
specif
nonspecif
detect
infect
develop
radiolabel
antibiot
bacteria
progress
faster
gain
popular
due
simpl
radiolabel
procedur
tco
higher
avail
fluoroquinolon
antibiot
specif
bind
inhibit
bacteri
dna
gyras
tcciprofloxacin
one
first
radiolabel
antibiot
imag
microbi
infect
asept
inflamm
ciprofloxacin
label
use
formamidin
sulfur
acid
fsa
tc
reduc
agent
min
howev
due
instabl
fsa
stannou
ion
use
increas
label
yield
reduc
tc
lower
oxid
state
afterward
http
receiv
januari
receiv
revis
form
februari
accept
februari
tcciprofloxacin
approv
infect
imag
market
fluoroquinolon
famili
antibiot
also
label
purpos
improv
product
altern
sever
acut
respiratori
syndrom
sar
antibiot
grow
drug
resist
varieti
tclabel
flouroquinolon
cephalosporin
antibiot
prepar
includ
tcpefloxacin
tclomefloxacin
tcofloxacin
tcsparafloxacin
tcdifloxacin
tcmoxifloxacin
tcgemifloxacin
tcrufloxacin
tcclinafloxacin
tcsitafloxacin
tclevofloxacin
tctemafloxacin
tcceftizoxim
tccefuroxim
tcceftriaxon
tccefotaxim
tccefoperazon
radiolabel
antibiot
use
diagnosi
infect
advantag
util
radiolabel
antibiot
abil
differenti
infect
asept
inflamm
levofloxacin
broadspectrum
antibiot
belong
thirdgener
fluoroquinolon
antibacteri
activ
optic
activ
lisom
ofloxacin
antibacteri
activ
levofloxacin
due
blockag
bacteri
cell
growth
inhibit
dna
gyras
bacteri
topoisomeras
ii
enzym
requir
dna
replic
rna
transcript
repair
bacteri
dna
agent
scintigraph
imag
develop
perform
quick
effici
imag
inflamm
infect
high
sensit
specif
radiolabel
liposom
design
imag
agent
inflamm
infecti
process
previous
demonstr
liposom
small
particl
size
surfac
coat
hydrophil
polym
peg
show
enhanc
blood
circul
time
provid
increas
accumul
site
infect
liposom
formul
particl
size
nanomet
rang
surfac
coat
passiv
target
call
stealth
liposom
varieti
stealth
liposom
prepar
evalu
purpos
although
mani
previou
studi
perform
tcradiolabel
antibiot
liposom
techniqu
still
valuabl
accumul
site
infect
inflamm
infect
specif
radiopharmaceut
success
use
diagnosi
imag
therapi
monitor
intens
research
develop
specif
infect
inflamm
imag
probe
routin
use
tracer
clinic
still
evalu
infect
inflamm
effici
although
micel
anoth
effici
use
deliveri
system
imag
therapi
mani
diseas
research
diagnosi
imag
infect
inflamm
micel
limit
micel
form
lipid
monolay
fatti
acid
core
polar
surfac
invert
micel
defin
viceversa
micel
polar
core
center
fatti
acid
surfac
therefor
research
evalu
infect
inflamm
potenti
micel
may
benefici
tclevofloxacin
radiolabel
two
studi
differ
radiolabel
method
includ
coligand
vivo
efficaci
tclevofloxacin
infect
model
small
anim
found
high
studi
howev
vitro
bacteri
bind
tclevofloxacin
never
investig
compar
tclabel
pegyl
phosphatidylcholin
pc
sodium
dodecyl
cholat
sdc
dtpape
contain
nanos
micel
studi
pegyl
pc
sdc
dtpape
contain
nanos
micel
design
micel
levofloxacin
radiolabel
tco
tin
reduct
method
develop
potenti
radiotrac
detect
infect
inflamm
aim
studi
formul
compar
radiolabel
micel
radiolabel
antibacteri
agent
levofloxacin
infect
inflamm
agent
differ
mechan
accumul
infect
inflamm
site
radiolabel
tclevofloxacin
evalu
chang
antibiot
concentr
reduc
agent
sncl
concentr
ph
incub
time
among
process
radioact
kept
constant
percent
label
tclevofloxacin
measur
use
itlc
plate
character
studi
perform
tcradiolabel
micel
radiolabel
effici
also
evalu
bacteri
bind
tclabel
levofloxacin
micel
compar
staphylococcu
aureu
aureu
escherichia
coli
e
coli
evalu
compar
vitro
bacteri
bind
specif
potenti
infect
inflamm
imag
agent
levofloxacin
hemihydr
obtain
drogsan
turkey
phosphatidylcholin
soybean
pc
kind
gift
lipoid
gmbh
germani
sodium
dodecyl
cholat
sdc
obtain
sigmaaldrich
usa
tin
ii
chlorid
obtain
sigmaaldrich
usa
radiolabel
procedur
perform
determin
best
condit
label
levofloxacin
tco
label
effici
calcul
chang
sncl
concentr
levofloxacin
concentr
mg
ph
incub
time
min
amount
sodium
pertechnet
mci
freshli
elut
mo
tc
gener
ph
arrang
use
n
hcl
naoh
solut
radiochem
puriti
evalu
itlc
use
miniatur
itlcsg
plate
evalu
percentag
unbound
pertechnet
tco
hydrolyzedreduc
technetium
tco
use
aceton
salin
run
solvent
respect
tclevofloxacin
spot
itlc
plate
radiochem
puriti
tclevofloxacin
measur
use
equat
purpos
obtain
effici
maximum
radiolabel
optimum
amount
levofloxacin
reduc
agent
ph
incub
time
evalu
highest
radiolabel
yield
calcul
pass
tclevofloxacin
filter
itlc
analysi
dtpape
use
chelat
agent
radiolabel
micel
synthet
mix
mm
dope
ml
chloroform
supplement
triethylamin
ad
mm
dtpa
anhydrid
ml
dmso
stir
mixtur
incub
h
argon
ga
afterward
solut
dialyz
l
water
h
purifi
dtpape
freezedri
store
frozen
film
form
method
use
prepar
pegyl
dtpape
contain
micel
contain
pc
sdc
dtpape
molar
ratio
lipid
mg
total
lipidsml
dissolv
chloroform
evapor
reduc
pressur
remov
solvent
lipid
film
hydrat
hepe
ph
buffer
afterward
vesicl
dispers
min
via
ultrason
character
pegyl
pc
sdc
dtpape
contain
nanos
micel
determin
measur
mean
particl
size
zeta
potenti
mean
particl
size
polydispers
index
pdi
zeta
potenti
micel
measur
use
nanoz
malvern
instrument
malvern
uk
dynam
light
scatter
method
qualiti
control
bind
check
itlcsg
plate
salin
aceton
run
solvent
system
complet
develop
procedur
strip
cut
measur
well
type
gamma
counter
vitro
stabil
tclevofloxacin
radiolabel
pegyl
pc
sdc
contain
micel
determin
room
temperatur
presenc
salin
nacl
wv
serum
purpos
ml
sampl
ad
ml
salin
equal
volum
cell
cultur
medium
pb
supplement
fb
afterward
analyz
incub
itlc
h
estim
radiochem
stabil
tclevofloxacin
radiolabel
micel
vitro
bind
effici
tclevofloxacin
tc
radiolabel
pegyl
pc
sdc
micel
investig
aureu
e
coli
evalu
bacteri
bind
ml
bacteri
suspens
contain
approxim
cfu
taken
exactli
ml
pb
contain
approxim
mci
radiolabel
levofloxacin
micel
ad
test
tube
mixtur
incub
h
afterward
centrifug
min
rpm
pellet
resuspend
ml
pb
resuspend
pellet
centrifug
min
supernat
separ
ml
pb
ad
supernat
remov
radioact
bacteri
pellet
determin
welltyp
gamma
counter
bacteri
bind
radiopharmaceut
calcul
accord
equat
bacteri
bind
count
pellet
count
supernat
count
pellet
valu
express
mean
sd
n
nonparametr
test
method
use
evalu
number
data
less
depend
group
number
student
test
use
comparison
two
group
kruskal
walli
use
comparison
three
group
signific
level
set
p
tclevofloxacin
tcradiolabel
micel
prepar
purpos
effect
infect
inflamm
imag
pegyl
pc
sdc
dtpape
contain
nanos
micel
prepar
radiolabel
imag
infect
inflamm
character
micel
perform
measur
particl
size
zeta
potenti
averag
particl
size
micel
nm
polydispers
index
zeta
potenti
mv
nanos
pegyl
pc
sdc
dtpape
contain
micel
show
high
label
effici
optim
radiolabel
provid
best
condit
obtain
maximum
label
effici
tc
radiolabel
levofloxacin
tri
vari
condit
label
yield
optim
radiolabel
effici
levofloxacin
perform
vari
concentr
mg
amount
radioact
best
radiolabel
effici
levofloxacin
achiev
addit
mg
levofloxacin
observ
lesser
amount
levofloxacin
result
decreas
label
effici
radiolabel
effici
mg
levofloxacin
higher
amount
mg
result
signific
alter
label
effici
find
agreement
literatur
reduc
agent
sncl
use
rang
evalu
optimum
amount
sncl
achiev
highest
label
effici
observ
low
amount
reduc
agent
label
effici
low
highest
radiolabel
efficieni
obtain
ml
sncl
may
conclud
lower
amount
lower
ml
reduc
agent
effect
reduc
whole
tco
label
process
fig
observ
agreement
previou
studi
differ
ph
valu
evalu
determin
effect
ph
radiolabel
efficieni
signific
differ
label
yield
acid
condit
observ
hand
label
effici
decreas
slight
basic
ph
may
due
possibl
chang
structur
levofloxacin
relat
carboxyl
moieti
basic
ph
fig
carboxyl
moieti
may
neutral
prevent
label
tco
metal
exchang
reaction
maximum
radiolabel
achiev
higher
lower
ph
valu
caus
decreas
label
effici
observ
paralel
studi
incub
time
essenti
paramet
radiolabel
effici
radiopharmaceut
effect
incub
time
label
effici
tclevofloxacin
given
fig
maximum
radiolabel
effici
obtain
min
incub
levofloxacin
sodium
pertechnet
observ
longer
incub
time
caus
signific
differ
radiolabel
effici
agreement
literatur
evalu
effect
chang
antibiot
concentr
reduc
agent
concentr
ph
conclud
maximum
label
effici
achiev
use
mg
levofloxacin
sncl
dissolv
ml
salin
ph
incub
sodium
pertechnet
mci
min
afterward
radiolabel
levofloxacin
filter
filter
room
temperatur
highest
radiolabel
yield
observ
paralel
previou
studi
accord
stabil
test
perform
room
temperatur
radiolabel
effici
remain
stabl
insignific
alter
degrad
carri
h
tabl
signific
differ
observ
serum
salin
stabil
tclevofloxacin
tcmicel
agreement
literatur
vitro
bacteri
bind
radiolabel
levofloxacin
micel
aureu
incub
observ
respect
vitro
e
coli
bind
radiolabel
levofloxacin
micel
show
respect
fig
radiolabel
levofloxacin
micel
show
high
vitro
bacteri
bind
radiolabel
pc
sdc
micel
exhibit
lesser
bacteri
bind
aureu
e
coli
cultur
p
may
due
fact
tcradiolabel
pc
sdc
micel
specif
bacteri
infect
much
tclevofloxacin
howev
radiolabel
pc
sdc
micel
also
assum
sensit
radiopharmaceut
agent
due
mechan
imag
infect
inflamm
tcradiolabel
pegyl
pc
sdc
dtpape
contain
nanos
micel
accumul
infect
inflamm
site
due
long
vascular
circul
vesicl
small
particl
size
surfac
coat
hydrophil
polym
peg
report
previou
studi
accumul
radiolabel
liposom
infecti
site
perform
leakag
vesicl
vessel
leakag
depend
enhanc
vascular
permeabl
follow
phagocythosi
macrophag
infect
tissu
report
endotheli
junction
exist
blood
vessel
provid
penetr
particl
smaller
nm
vascular
therefor
surfac
coat
nanos
drug
deliveri
system
like
liposom
accumul
site
infect
inflamm
due
long
circul
enhanc
vascular
permeabl
reduc
remov
opsonis
therefor
tclevofloxacin
tcradiolabel
nanos
pegyl
pc
sdc
dtpape
contain
micel
observ
potenti
imag
agent
diagnosi
imag
inflamm
infecti
site
despit
radiolabel
antibiot
could
repres
promis
tool
specif
imag
infect
process
radiolabel
micel
show
similar
specif
mechan
accumul
infectiousinflammatori
site
mainli
due
increas
permeabl
present
infect
inflammatori
process
small
particl
size
therefor
passiv
nonspecif
mechan
impli
could
use
monitor
inflammatori
burden
sinc
radiolabel
micel
abl
discrimin
infect
steril
inflamm
use
imag
infect
limit
clinic
practic
radiolabel
compound
nanocarri
lead
direct
research
toward
easi
quick
diagnosi
imag
infect
inflamm
although
radiolabel
levofloxacin
particularli
excel
altern
detect
chronic
infect
caus
gramposit
gramneg
bacteria
radiolabel
pegyl
pc
sdc
dtpape
contain
nanos
micel
also
evalu
potenti
candid
detect
infect
inflamm
known
micel
similar
liposom
tend
accumul
site
infect
base
long
vascular
circul
vesicl
small
particl
size
surfac
coat
hydrophil
polym
peg
radiopharmaceut
agent
exhibit
potenti
result
design
character
radiolabel
effici
vitro
bacteri
bind
point
view
vivo
potenti
radiolabel
levofloxacin
micel
also
evalu
infect
inflamm
anim
model
futur
asuman
yekta
ozer
write
review
edit
author
state
decler
interest
